{"protocolSection": {"identificationModule": {"nctId": "NCT01342484", "orgStudyIdInfo": {"id": "1218.56"}, "secondaryIdInfos": [{"id": "2009-017004-91", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes", "officialTitle": "A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2016-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-04"}, "primaryCompletionDateStruct": {"date": "2016-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-04-26", "studyFirstSubmitQcDate": "2011-04-26", "studyFirstPostDateStruct": {"date": "2011-04-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-07-27", "resultsFirstSubmitQcDate": "2016-07-27", "resultsFirstPostDateStruct": {"date": "2016-09-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-07-27", "lastUpdatePostDateStruct": {"date": "2016-09-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}, "collaborators": [{"name": "Eli Lilly and Company", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "The main objective of this study is to identify the dose of linagliptin in paediatric patients.\n\nOther efficacy objectives include the comparison of the lowering effect of linagliptin low dose, high dose and placebo on the fasting plasma glucose (FPG) observed after 12 wk of treatment.\n\nFurthermore, the study will investigate the pharmacokinetics (PK), the pharmacodynamics (PD) and the PK/PD relationship of linagliptin in the paediatric population."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 40, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "linagliptin low dose", "type": "EXPERIMENTAL", "description": "linagliptin low dose for children once daily", "interventionNames": ["Drug: BI1356 low dose"]}, {"label": "linagliptin high dose", "type": "EXPERIMENTAL", "description": "linagliptin high dose for children once daily", "interventionNames": ["Drug: BI1356 high dose"]}, {"label": "placebo", "type": "PLACEBO_COMPARATOR", "description": "matching placebo for each linagliptin dose once daily", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "placebo", "description": "comparison of different dosages of drug (low vs high) vs placebo", "armGroupLabels": ["placebo"]}, {"type": "DRUG", "name": "BI1356 low dose", "description": "comparison of different dosages of drug (low vs high) vs placebo", "armGroupLabels": ["linagliptin low dose"]}, {"type": "DRUG", "name": "BI1356 high dose", "description": "comparison of different dosages of drug (low vs high) vs placebo", "armGroupLabels": ["linagliptin high dose"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment", "description": "Change from baseline in Glycosylated haemoglobin (HbA1c) \\[%\\] after 12 weeks of treatment with double-blind trial medication. Baseline was defined as the last observation before the first intake of any double-blind randomised trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.", "timeFrame": "Baseline and 12 weeks"}], "secondaryOutcomes": [{"measure": "Dipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State", "description": "DPP-4 inhibition (%) at trough at steady state is the relative change between the measurement of DPP-4 activity taken 0.5 hours before dosing at baseline and the first available on-treatment measurement of DPP-4 activity taken 0.5 hour before dosing at week 4, 8 or 12: DPP-4 inhibition (%) = 100 - (DPP-4 activity at week X / DPP-4 activity at baseline) x 100.", "timeFrame": "Baseline and 4 weeks or 8 weeks or 12 weeks"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment", "description": "Change from baseline in FPG (mmol/L) after 12 weeks of treatment with double-blind trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.", "timeFrame": "Baseline and 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Paediatric patients (children and adolescents), aged 10 to 17 years with documented diagnosis of type 2 diabetes mellitus\n2. Insufficient glycaemic control (i.e. an HbA1c \\> 6.5% and \\<= 10.5%) despite treatment with diet and exercise and/or metformin (\\>= 1000 mg per day (or the maximum tolerated dose) at a stable dose or dosing frequency for 8 weeks prior to randomisation) and/or concomitant stable basal insulin (total daily dose must be \\<= 0.5U/kg with less than 10% of weekly dose change for 12 weeks prior to randomisation)\n3. Negative for islet cell antigen (ICA) auto-antibodies and glutamic acid decarboxylase (GAD) auto-antibodies\n4. C-peptide levels (serum) \\>= 1.5 ng/ml (at 90 min following a Boost challenge)\n\nExclusion criteria:\n\n1. History of acute metabolic decompensation, such as diabetic ketoacidosis, within 3 months\n2. Current short-acting insulin or having received short-acting insulin for more than 3 days within 1 month prior to randomisation\n3. Treatment with weight reduction medications (including anti-obesity treatments)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "10 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1218.56.01006 Boehringer Ingelheim Investigational Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "1218.56.01004 Boehringer Ingelheim Investigational Site", "city": "Norfolk", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "1218.56.11001 Boehringer Ingelheim Investigational Site", "city": "Montreal", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "1218.56.33003 Boehringer Ingelheim Investigational Site", "city": "Fort de France cedex", "country": "France"}, {"facility": "1218.56.33006 Boehringer Ingelheim Investigational Site", "city": "Rouen", "country": "France", "geoPoint": {"lat": 49.44313, "lon": 1.09932}}, {"facility": "1218.56.50202 Boehringer Ingelheim Investigational Site", "city": "Guatemala", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "1218.56.50203 Boehringer Ingelheim Investigational Site", "city": "Guatemala", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "1218.56.39005 Boehringer Ingelheim Investigational Site", "city": "Firenze", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "1218.56.82005 Boehringer Ingelheim Investigational Site", "city": "Busan", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "1218.56.82001 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1218.56.82002 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1218.56.82003 Boehringer Ingelheim Investigational Site", "city": "Suwon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "1218.56.52008 Boehringer Ingelheim Investigational Site", "city": "Chihuahua", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"facility": "1218.56.52002 Boehringer Ingelheim Investigational Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "1218.56.52001 Boehringer Ingelheim Investigational Site", "city": "Le\u00f3n", "country": "Mexico", "geoPoint": {"lat": 21.12908, "lon": -101.67374}}, {"facility": "1218.56.52003 Boehringer Ingelheim Investigational Site", "city": "Monterrey", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "1218.56.52004 Boehringer Ingelheim Investigational Site", "city": "Oaxaca", "country": "Mexico", "geoPoint": {"lat": 17.06542, "lon": -96.72365}}, {"facility": "1218.56.48002 Boehringer Ingelheim Investigational Site", "city": "Gdansk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "1218.56.48001 Boehringer Ingelheim Investigational Site", "city": "Gliwice", "country": "Poland", "geoPoint": {"lat": 50.29761, "lon": 18.67658}}, {"facility": "1218.56.48004 Boehringer Ingelheim Investigational Site", "city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "1218.56.48003 Boehringer Ingelheim Investigational Site", "city": "Wroclaw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "1218.56.70001 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "1218.56.70003 Boehringer Ingelheim Investigational Site", "city": "Saratov", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "1218.56.70004 Boehringer Ingelheim Investigational Site", "city": "Ufa", "country": "Russian Federation", "geoPoint": {"lat": 54.74306, "lon": 55.96779}}, {"facility": "1218.56.70006 Boehringer Ingelheim Investigational Site", "city": "Yekaterinburg", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All patients suitable after screening underwent a 2-week open-label placebo run-in period before randomisation. Patients who successfully completed this period and who still met the inclusion/exclusion criteria were randomised to the 12-week randomised period in which they received either 1 of the 2 doses of linagliptin or placebo.", "recruitmentDetails": "Randomised, double-blind, placebo-controlled parallel group dose-finding study of linagliptin over 12 weeks in children and adolescents, from 10 to 17 years of age, with type 2 diabetes mellitus. Due to serious Good clinical practice (GCP) breach, 1 patient excluded from all analyses. So protocol section has 40 subjects and participant flow has 39", "groups": [{"id": "FG000", "title": "Placebo", "description": "Matching placebo dose was administered orally once daily for 12 weeks"}, {"id": "FG001", "title": "Linagliptin 1 mg", "description": "Linagliptin 1 mg dose was administered orally once daily for 12 weeks"}, {"id": "FG002", "title": "Linagliptin 5 mg", "description": "Linagliptin 5 mg dose was administered orally once daily for 12 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Other Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated set (TS) including all patients who were treated with at least one dose of study drug.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Matching placebo dose was administered orally once daily for 12 weeks"}, {"id": "BG001", "title": "Linagliptin 1 mg", "description": "Linagliptin 1 mg dose was administered orally once daily for 12 weeks"}, {"id": "BG002", "title": "Linagliptin 5 mg", "description": "Linagliptin 5 mg dose was administered orally once daily for 12 weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "39"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13.7", "spread": "2.0"}, {"groupId": "BG001", "value": "14.0", "spread": "1.8"}, {"groupId": "BG002", "value": "14.3", "spread": "2.1"}, {"groupId": "BG003", "value": "14.0", "spread": "1.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "21"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "18"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment", "description": "Change from baseline in Glycosylated haemoglobin (HbA1c) \\[%\\] after 12 weeks of treatment with double-blind trial medication. Baseline was defined as the last observation before the first intake of any double-blind randomised trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.", "populationDescription": "Full analysis set (FAS) including all randomised patients who were treated with at least one dose of study drug and had a baseline and at least one on-treatment HbA1c assessment. Observed Case (OC): In the OC analysis, values after the use of rescue medication were set to missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of HbA1c", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching placebo dose was administered orally once daily for 12 weeks"}, {"id": "OG001", "title": "Linagliptin 1 mg", "description": "Linagliptin 1 mg dose was administered orally once daily for 12 weeks"}, {"id": "OG002", "title": "Linagliptin 5 mg", "description": "Linagliptin 5 mg dose was administered orally once daily for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.45", "spread": "0.31"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.38"}, {"groupId": "OG002", "value": "-0.19", "spread": "0.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Superiority of Linagliptin 1 mg vs. placebo: change from baseline in HbA1c using a restricted maximum likelihood (REML) - based mixed model repeated measures (MMRM) approach. Model includes baseline HbA1c and age as linear covariates; treatment, gender, pharmacokinetic (PK) / pharmacodynamics (PD) subgroup, background therapy, visit and visit by treatment interaction as fixed effects and patient as a random effect. The unstructured covariance structure has been used to fit the mixed model.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3295", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "The Kenward-Roger approximation was used to estimate denominator degrees of freedom.", "paramType": "Mean Difference (Net)", "paramValue": "-0.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.47", "ciUpperLimit": "0.51", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.48", "estimateComment": "Mean Difference (Net Values) is actually the adjusted mean difference calculated as Linagliptin 1 mg minus Placebo."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Superiority of Linagliptin 5 mg vs. placebo: change from baseline in HbA1c using a restricted maximum likelihood (REML) - based mixed model repeated measures (MMRM) approach. Model includes baseline HbA1c and age as linear covariates; treatment, gender, PK/PD subgroup, background therapy, visit and visit by treatment interaction as fixed effects and patient as a random effect. The unstructured covariance structure has been used to fit the mixed model.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1447", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "The Kenward-Roger approximation was used to estimate denominator degrees of freedom.", "paramType": "Mean Difference (Net)", "paramValue": "-0.63", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.50", "ciUpperLimit": "0.23", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.42", "estimateComment": "Mean Difference (Net Values) is actually the adjusted mean difference calculated as Linagliptin 5 mg minus Placebo."}]}, {"type": "SECONDARY", "title": "Dipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State", "description": "DPP-4 inhibition (%) at trough at steady state is the relative change between the measurement of DPP-4 activity taken 0.5 hours before dosing at baseline and the first available on-treatment measurement of DPP-4 activity taken 0.5 hour before dosing at week 4, 8 or 12: DPP-4 inhibition (%) = 100 - (DPP-4 activity at week X / DPP-4 activity at baseline) x 100.", "populationDescription": "Full analysis set (FAS) including all randomised patients who were treated with at least one dose of study drug and had a baseline and at least one on-treatment HbA1c assessment. OR (Original Results). The analysis excludes placebo patients and 1 FAS patient from Linagliptin 1 mg group.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Percentage of DPP-4 inhibition", "timeFrame": "Baseline and 4 weeks or 8 weeks or 12 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching placebo dose was administered orally once daily for 12 weeks"}, {"id": "OG001", "title": "Linagliptin 1 mg", "description": "Linagliptin 1 mg dose was administered orally once daily for 12 weeks"}, {"id": "OG002", "title": "Linagliptin 5 mg", "description": "Linagliptin 5 mg dose was administered orally once daily for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "38.4", "lowerLimit": "26.9", "upperLimit": "48.8"}, {"groupId": "OG002", "value": "78.9", "lowerLimit": "67.7", "upperLimit": "84.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment", "description": "Change from baseline in FPG (mmol/L) after 12 weeks of treatment with double-blind trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.", "populationDescription": "Full analysis set (FAS) including all randomised patients who were treated with at least one dose of study drug and had a baseline and at least one on-treatment HbA1c assessment. Observed Case (OC): In the OC analysis, values after the use of rescue medication were set to missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching placebo dose was administered orally once daily for 12 weeks"}, {"id": "OG001", "title": "Linagliptin 1 mg", "description": "Linagliptin 1 mg dose was administered orally once daily for 12 weeks"}, {"id": "OG002", "title": "Linagliptin 5 mg", "description": "Linagliptin 5 mg dose was administered orally once daily for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.70", "spread": "0.85"}, {"groupId": "OG001", "value": "1.39", "spread": "1.07"}, {"groupId": "OG002", "value": "-0.19", "spread": "0.83"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Superiority of Linagliptin 1 mg vs. placebo: change from baseline in FPG using a restricted maximum likelihood (REML) - based mixed model repeated measures (MMRM) approach. Model includes baseline HbA1c, baseline FPG and age as linear covariates; treatment, gender, PK/PD subgroup, background therapy, visit and visit by treatment interaction as fixed effects and patient as a random effect. The unstructured covariance structure has been used to fit the mixed model.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8216", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "The Kenward-Roger approximation was used to estimate denominator degrees of freedom.", "paramType": "Mean Difference (Net)", "paramValue": "-0.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.08", "ciUpperLimit": "2.46", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.36", "estimateComment": "Mean Difference (Net Values) is actually the adjusted mean difference calculated as Linagliptin 1 mg minus Placebo."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Superiority of Linagliptin 5 mg vs. placebo: change from baseline in FPG using a restricted maximum likelihood (REML) - based mixed model repeated measures (MMRM) approach. Model includes baseline HbA1c, baseline FPG and age as linear covariates; treatment, gender, PK/PD subgroup, background therapy, visit and visit by treatment interaction as fixed effects and patient as a random effect. The unstructured covariance structure has been used to fit the mixed model.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1189", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "The Kenward-Roger approximation was used to estimate denominator degrees of freedom.", "paramType": "Mean Difference (Net)", "paramValue": "-1.90", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.31", "ciUpperLimit": "0.52", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.18", "estimateComment": "Mean Difference (Net Values) is actually the adjusted mean difference calculated as Linagliptin 5 mg minus Placebo."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From the first intake of study drug until 7 days after the last drug administration, up to 13 weeks.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Matching placebo dose was administered orally once daily for 12 weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 15, "otherNumAffected": 7, "otherNumAtRisk": 15}, {"id": "EG001", "title": "Linagliptin 1 mg", "description": "Linagliptin 1 mg dose was administered orally once daily for 12 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 8, "otherNumAtRisk": 10}, {"id": "EG002", "title": "Linagliptin 5 mg", "description": "Linagliptin 5 mg dose was administered orally once daily for 12 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 6, "otherNumAtRisk": 14}], "seriousEvents": [{"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}], "otherEvents": [{"term": "Hyperthyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Eye haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Lip oedema", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Conjunctivitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Vulvovaginitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 14}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Menorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Skin hyperpigmentation", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim, Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "New Zealand", "Peru"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069476", "term": "Linagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M445", "name": "Linagliptin", "asFound": "Exit", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}